These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23052409)

  • 1. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.
    Guo D; Pang LF; Han Y; Yang H; Wang G; Tan ZR; Zhang W; Zhou HH
    Eur J Clin Pharmacol; 2013 Apr; 69(4):843-9. PubMed ID: 23052409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
    Xie XC; Li J; Wang HY; Li HL; Liu J; Fu Q; Huang JW; Zhu C; Zhong GP; Wang XD; Sun PP; Huang M; Wang CX; Li JL
    Acta Pharmacol Sin; 2015 May; 36(5):644-50. PubMed ID: 25864649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
    Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
    Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
    Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of UDP-Glucuronosyltransferase Polymorphisms on Mycophenolic Acid Metabolism in Renal Transplant Patients.
    Xu C; Jiang Z; Qian M; Zuo L; Xue H; Hu N
    Transplant Proc; 2024; 56(6):1280-1289. PubMed ID: 39054222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.
    Jiao Z; Ding JJ; Shen J; Liang HQ; Zhong LJ; Wang Y; Zhong MK; Lu WY
    Br J Clin Pharmacol; 2008 Jun; 65(6):893-907. PubMed ID: 18279479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.
    Lévesque E; Benoit-Biancamano MO; Delage R; Couture F; Guillemette C
    Pharmacogenomics; 2008 Jul; 9(7):869-79. PubMed ID: 18597651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
    Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
    Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
    Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
    Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA
    Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
    Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
    Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
    Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.
    Zhang Q; Tao Y; Zhu Y; Zhu D
    Clin Ther; 2010 Jan; 32(1):171-8. PubMed ID: 20171422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.
    Dostalek M; Court MH; Hazarika S; Akhlaghi F
    Drug Metab Dispos; 2011 Mar; 39(3):448-55. PubMed ID: 21123165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: A population analysis.
    Yang CL; Sheng CC; Liao GY; Su Y; Feng LJ; Xia Q; Jiao Z; Xu DJ
    J Clin Pharm Ther; 2021 Dec; 46(6):1564-1575. PubMed ID: 34312870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients.
    Ruschel LR; Schmitt VM; Silva AB; Oliveira CSA; Flach K; d'Avila DO; Thiesen FV
    Genet Mol Res; 2017 May; 16(2):. PubMed ID: 28613375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil.
    Ling J; Shi J; Jiang Q; Jiao Z
    Eur J Clin Pharmacol; 2015 Jan; 71(1):95-106. PubMed ID: 25327506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.